Foreign Firms Land 3 Pentagon Defense Contracts
Subsidiaries of Hikma Pharma, Bayer, and Finmeccanica all win contracts.
Regeneron's Eylea: The Anatomy Of A Blockbuster Drug
Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year.
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Roche, Regeneron, Cell Therapeutics, and AstraZeneca could all make health-care headlines this morning. Here's why.
What You Need to Know About Seattle Genetics' Biggest Growth Driver
Seattle Genetics (SGEN) successful Hodgkin's lymphoma drug Adcetris has an opportunity for significant growth if ongoing trials succeed.
Regeneron Pharmaceuticals' Q4 Profit Surges 51% on Strong Eylea Sales
Impressive Eylea sales growth within and outside the U.S., as well as increased collaborative revenue, pushes Regeneron's profit up 51%.
Today's Biggest Biotech Stories: Roche, Merck, Bayer, and Regeneron
Roche, Merck, Bayer, and Regeneron could make health care headlines this morning. Here’s why.
Here's Why Big Pharma is Rooting for Portola
Pfizer (PFE), Bristol-Myers (BMY), Johnson & Johnson (JNJ) and Bayer (BAYRY) stand to make big money if Portola's anti-coagulant antidote succeeds.
Sales of Pfizer Inc. and Bristol-Myers Squibb Co.'s Eliquis Thicken
Pfizer (PFE) and Bristol's (BMY) blood thinning drug Eliquis may be gaining ground on Johnson & Johnson (JNJ) and Boehringer.
Acetaminophen: 4 Things to Know About This Common Over-the-Counter Drug
The FDA recently issued a warning regarding liver damage caused by acetaminophen. Here are four things consumers and investors need to know about the drug, and how it could affect companies like Johnson & Johnson, Novartis, GlaxoSmithKline, and Zogenix.